Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Phase 1 CML-041 Results on Combination of Asciminib, a Novel and Specific BCRABL1 Inhibitor, Plus Imatinib in Previously Treated CML

7 views
November 18, 2019
0 Comments
Login to view comments. Click here to Login